Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany.
Eur J Endocrinol. 2013 Oct 1;169(5):547-57. doi: 10.1530/EJE-13-0112. Print 2013 Nov.
Adipose tissue-derived factors link non-alcoholic fatty liver disease (NAFLD) with obesity, which has also been reported for circulating chemerin. On the other hand, hepatic chemerin and chemokine-like receptor 1 (CMKLR1) mRNA expression has not yet been studied in an extensively characterized patient collective.
This study was cross-sectional and experimental in design.
Liver tissue samples were harvested from 47 subjects and histologically examined according to the NAFLD activity score (NAS). The concentrations of chemerin and CMKLR1 were measured using semi-quantitative real-time PCR, and the concentration of serum chemerin was measured using ELISA. To evaluate potential effects of chemerin and CMKLR1, cultured primary human hepatocytes (PHHs) were exposed to selected metabolites known to play a role in NAFLD (insulin, glucagon, palmitoic acid, and interleukin-6 (IL6)).
Chemerin and CMKLR1 mRNA levels were elevated in the human liver. Their expression was correlated with the NAS (R(2)=0.543; P<0.001 and R(2)=0.355; P=0.014 respectively) and was significantly elevated in patients with definite non-alcoholic steatohepatitis (NASH) (P<0.05 respectively). Linear regression analysis confirmed an independent association of liver fibrosis, steatosis, inflammation, and hepatocyte ballooning with hepatic chemerin mRNA expression (P<0.05 respectively). The expression of hepatic chemerin and CMKLR1 was correlated with the measures of obesity (P<0.05). The incubation of PHHs with IL6 significantly increased the expression of CMKLR1 mRNA (P=0.027), while that of chemerin remained unaffected (P>0.05). None of the other metabolites showed an influence (P>0.05).
This is the first study to show that chemerin mRNA expression is significantly elevated in the liver of NASH patients and that CMKLR1 expression is upregulated in liver inflammation, whereby IL6 could play a causal role.
脂肪组织衍生因子将非酒精性脂肪性肝病(NAFLD)与肥胖联系起来,循环趋化素也有报道。另一方面,肝趋化素和趋化素样受体 1(CMKLR1)mRNA 的表达尚未在广泛特征化的患者群体中进行研究。
本研究为横断面和实验设计。
从 47 名患者中采集肝组织样本,并根据 NAFLD 活动评分(NAS)进行组织学检查。使用半定量实时 PCR 测量趋化素和 CMKLR1 的浓度,并使用 ELISA 测量血清趋化素的浓度。为了评估趋化素和 CMKLR1 的潜在作用,将培养的原代人肝细胞(PHH)暴露于已知在 NAFLD 中起作用的选定代谢物(胰岛素、胰高血糖素、棕榈酸和白细胞介素 6(IL6))。
趋化素和 CMKLR1 的 mRNA 水平在人肝中升高。它们的表达与 NAS 相关(R(2)=0.543;P<0.001 和 R(2)=0.355;P=0.014),并且在明确的非酒精性脂肪性肝炎(NASH)患者中显著升高(P<0.05)。线性回归分析证实肝纤维化、脂肪变性、炎症和肝细胞气球样变与肝趋化素 mRNA 表达独立相关(P<0.05)。肝趋化素和 CMKLR1 的表达与肥胖的指标相关(P<0.05)。IL6 孵育 PHH 可显著增加 CMKLR1 mRNA 的表达(P=0.027),而趋化素的表达不受影响(P>0.05)。其他代谢物均无影响(P>0.05)。
这是第一项表明 NASH 患者肝中趋化素 mRNA 表达显著升高,并且 CMKLR1 表达在肝炎症中上调的研究,其中 IL6 可能起因果作用。